40 related articles for article (PubMed ID: 8053388)
1. Effects of increasing doses of 1 alpha-hydroxyvitamin D2 on calcium homeostasis in postmenopausal osteopenic women.
Gallagher JC; Bishop CW; Knutson JC; Mazess RB; DeLuca HF
J Bone Miner Res; 1994 May; 9(5):607-14. PubMed ID: 8053388
[TBL] [Abstract][Full Text] [Related]
2. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
[TBL] [Abstract][Full Text] [Related]
3. Oral 1,25-dihydroxyvitamin D administration in osteoporotic women: effects of estrogen therapy.
Cosman F; Nieves J; Shen V; Lindsay R
J Bone Miner Res; 1995 Apr; 10(4):594-600. PubMed ID: 7610930
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D2 dose required to rapidly increase 25OHD levels in osteoporotic women.
Mastaglia SR; Mautalen CA; Parisi MS; Oliveri B
Eur J Clin Nutr; 2006 May; 60(5):681-7. PubMed ID: 16391587
[TBL] [Abstract][Full Text] [Related]
5. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
6. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
7. Effect of low-dose calcitriol and calcium therapy on bone histomorphometry and urinary calcium excretion in osteopenic women.
Arthur RS; Piraino B; Candib D; Cooperstein L; Chen T; West C; Puschett J
Miner Electrolyte Metab; 1990; 16(6):385-90. PubMed ID: 2089252
[TBL] [Abstract][Full Text] [Related]
8. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
9. Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women.
Yasui T; Miyatani Y; Tomita J; Yamada M; Uemura H; Miura M; Irahara M
Gynecol Endocrinol; 2006 Aug; 22(8):455-9. PubMed ID: 17012108
[TBL] [Abstract][Full Text] [Related]
10. Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers.
Schwietert HR; Groen EW; Sollie FA; Jonkman JH
Clin Pharmacol Ther; 1997 Mar; 61(3):360-76. PubMed ID: 9084461
[TBL] [Abstract][Full Text] [Related]
11. The effects of calcium supplementation (milk powder or tablets) and exercise on bone density in postmenopausal women.
Prince R; Devine A; Dick I; Criddle A; Kerr D; Kent N; Price R; Randell A
J Bone Miner Res; 1995 Jul; 10(7):1068-75. PubMed ID: 7484282
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
13. Reversal of vitamin-D2-induced hypercalciuria by chlorothiazide.
Alon U; Wellons MD; Chan JC
Pediatr Res; 1983 Feb; 17(2):117-9. PubMed ID: 6600835
[TBL] [Abstract][Full Text] [Related]
14. Toxicity and dose-response studies of 1 alpha-hydroxyvitamin D2 in LH beta-Tag transgenic mice.
Dawson DG; Gleiser J; Zimbric ML; Darjatmoko SR; Frisbie JC; Lokken JM; Lindstrom MJ; Audo I; Strugnell SA; Albert DM
Trans Am Ophthalmol Soc; 2002; 100():125-9. PubMed ID: 12545685
[TBL] [Abstract][Full Text] [Related]
15. Effects of 1 alpha OHD2 on bone tissue. Studies of 1 alpha OHD2 and 1 alpha OHD3 in normal rats and in rats treated with prednisolone.
Sjödén GO; Johnell O; DeLuca HF; Lindgren JU
Acta Endocrinol (Copenh); 1984 Aug; 106(4):564-8. PubMed ID: 6332445
[TBL] [Abstract][Full Text] [Related]
16. Effect of single large doses of oral calcium on serum calcium levels in the young and the elderly.
Epstein S; Van Mieghem W; Sagel J; Jackson WP
Metabolism; 1973 Sep; 22(9):1163-73. PubMed ID: 4542187
[No Abstract] [Full Text] [Related]
17. Vitamin D and Glomerulonephritis.
Gembillo G; Siligato R; Amatruda M; Conti G; Santoro D
Medicina (Kaunas); 2021 Feb; 57(2):. PubMed ID: 33671780
[TBL] [Abstract][Full Text] [Related]
18. Update on pharmacologically-relevant vitamin D analogues.
Jones G; Kaufmann M
Br J Clin Pharmacol; 2019 Jun; 85(6):1095-1102. PubMed ID: 30308088
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.
Wang X; Harrison JS; Studzinski GP
J Steroid Biochem Mol Biol; 2016 Nov; 164():72-78. PubMed ID: 26319201
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of oral doxercalciferol in the management of secondary hyperparathyroidism in chronic kidney disease stage 4.
Dheerendra PC; Sakhuja V; Kohli HS; Jha V
Indian J Nephrol; 2013 Jul; 23(4):271-5. PubMed ID: 23960343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
